1Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan
2Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan
3Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
4Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
5Department of Gastroenterology, Fukuoka University Chikushi Hospital, Fukuoka, Japan
6Department of Endoscopy, Fukuoka University Chikushi Hospital, Fukuoka, Japan
7Department of Gastroenterology, Fukui Prefectural Hospital, Fukui, Japan
8Department of Gastroenterology, Kochi Red Cross Hospital, Kochi, Japan
9Department of Preventive Medicine and Public Health, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
Copyright © 2023 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest
Eikichi Ihara has received lecture fees from Takeda Pharmaceutical Co., Ltd. The authors have no potential conflicts of interest.
Funding
None.
Acknowledgments
The authors thank H. Nikki March, PhD, from the Edanz Group (https://en-author-services.edanz.com/ac) for editing the draft of this manuscript.
Author Contributions
Conceptualization: AK, HD; Data curation: AK, KT, KU, TK, HM, RG, YM, EI, RA, KY, YN, HAo, TI, KU; Formal analysis: AK, KT; Supervision: NU, TK, HM, RG, YM, EI, RA, KY, YN, HAo, TI, KU, HAr, HD; Writing-original draft: AK, KT, HD; Writing-review & editing: all authors.
Demographic | SNADET (n=177) |
---|---|
Age (yr) | 65 (25–88) |
Sex | |
Male | 133 (75.1) |
Female | 44 (24.9) |
Tumor size (mm) | 12 (2–50) |
Tumor location | |
Bulb | 30 (16.9) |
Descending part, oral side of papilla | 63 (35.6) |
Descending part, anal side of papilla | 79 (44.6) |
Horizontal part | 5 (2.8) |
Macroscopic type of tumor | |
0–I | 32 (18.1) |
0–IIa | 120 (67.8) |
0–IIc | 25 (14.1) |
Histopathology | |
Category 3 | 71 (40.1) |
Category 4 | 106 (59.9) |
Category 5 | 0 (0) |
Characteristic | SNADET (n=177) | Control (n=531) | p-value |
---|---|---|---|
Median age (yr) | 65 (25–88) | 65 (25–88) | |
Sex | |||
Male | 133 (75.1) | 399 (75.1) | |
Female | 44 (24.9) | 132 (24.9) | |
H. pylori infection status | <0.001 | ||
Non-infection | 85 (48.0) | 112 (21.1) | |
Current infection | 37 (20.9) | 155 (29.2) | |
Past infection | 55 (31.1) | 264 (49.7) | |
Endoscopic gastric atrophy | <0.001 | ||
C0 | 83 (46.9) | 50 (9.4) | |
C1 | 13 (7.3) | 62 (11.7) | |
C2 | 26 (14.7) | 53 (10.0) | |
C3 | 12 (6.8) | 109 (20.5) | |
O1 | 21 (11.9) | 125 (23.6) | |
O2 | 11 (6.2) | 93 (17.5) | |
O3 | 11 (6.2) | 39 (7.3) |
Characteristic | Adjusted odds ratio (95% confidence interval) | p-value |
---|---|---|
Helicobacter pylori infection status | 0.15 | |
Non-infection | 1.10 (0.63–1.84) | |
Current/past infection | 1 | |
Endoscopic gastric atrophy | <0.001 | |
None | 5.10 (2.44–8.40) | |
Mild and severe | 1 |
Characteristic | Tumor location to major duodenal papilla |
p-value | |
---|---|---|---|
Oral side (n=93) | Anal side (n=84) | ||
H. pylori infection status | 0.30 | ||
Non-infection | 43 | 46 | |
Current/past infection | 50 | 38 | |
Endoscopic gastric atrophy | 0.23 | ||
None | 46 | 50 | |
Mild and severe | 47 | 34 |
Values are presented as median (range) or number (%). SNADET, superficial non-ampullary duodenal epithelial tumor; category 3, low-grade adenoma; category 4, high-grade adenoma/intramucosal carcinoma; category 5, submucosal invasive carcinomas.
Values are presented as median (range) or number (%). SNADET, superficial non-ampullary duodenal epithelial tumor.